Product Detail
Lurasidone Metabolite 14326-d8
Lurasidone Metabolite
Stock Status: In Stock
Login to view price
Live
For Research & Analytical Purposes. Not for Personal use.
Category
Metabolite
API Family
Lurasidone
Storage
Store at refrigerator (2-8°C) for long term storage
Hazard Information
Refer MSDS for complete information.
Lurasidone Metabolite 14326-d8 Product Information
Lurasidone Metabolite 14326-d8 is listed under Metabolite. It is associated with Lurasidone and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-O-02868.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Lurasidone Metabolite 14326-d8
CAS No.
2070009-33-3
CAT No.
CS-O-02868
Molecular Formula
C28H28D8N4O3S
Molecular Weight
516.72
Category
API Family
Storage Condition
Store at refrigerator (2-8°C) for long term storage
SMILES
O=C(N1C[C@H](CCCC2)[C@@H]2CN3C([2H])([2H])C([2H])([2H])N(C4=NSC5=CC=CC=C45)C([2H])([2H])C3([2H])[2H])[C@]6([H])[C@@](C1=O)([H])[C@]7([H])C[C@@]6([H])C[C@@H]7O
IUPAC Name
(1S,2S,6R,7S,8R)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)-2,2,3,3,5,5,6,6-octadeuteriopiperazin-1-yl]methyl]cyclohexyl]methyl]-8-hydroxy-4-azatricyclo[5.2.1.02,6]decane-3,5-dione
Purity by HPLC
99.04
Hazard Compound
Refer MSDS for complete information.
Description
Overview
"Labeled Lurasidone metabolite, intended for use as an internal standard for the quantification of Lurasidone by GC- or LC-mass spectrometry."
Synonyms
(1S,2S,6R,7S,8R)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)-2,2,3,3,5,5,6,6-octadeuteriopiperazin-1-yl]methyl]cyclohexyl]methyl]-8-hydroxy-4-azatricyclo[5.2.1.02,6]decane-3,5-dione
Application Notes
"Labeled Lurasidone metabolite, intended for use as an internal standard for the quantification of Lurasidone by GC- or LC-mass spectrometry."
References
"Corrigendum, Bipolar Disorders 10 (3): 451, 2008; Azorin, J,M,; Sapin, C,; Weiller, E, (2013)"
